Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 657.80

+1.7%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: A.J. Mullen	2/26/2021 8:17:15 PM
	of 3557

Possible competition for Dupixent a step closer, finance.yahoo.com Reuters) - AstraZeneca and Amgen's experimental drug , tezepelumab, cut the rate of asthma attacks by 56% among patients when compared to placebo in a year-long late-stage study, which had roughly 1,000 patients who were already receiving standard care, the drugmakers said on Friday. The biologic drug, if approved, will compete with AstraZeneca's own Fasenra and Regeneron's Dupixent.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next